Price Summary

FinStar

Ownership Stable

Ownership strength is slightly missing the benchmark.

ValuationAttractive

The stock is considerably attractive based on intrinsic value.

EfficiencyOptimal

The company could improve upon its asset employment.

FinancialsWeak

Watch out! The company might not be able to sustain any adverse condition.

Company Essentials

Market Cap

14963.38 Cr.

Enterprise Value

18448.88 Cr.

Book Value (TTM)

₹  541.64

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

CANDID ALEX-P SYRUP SIBUTRIM GLINATE LEREZ VORTH-XT STRONAT ERDOZET DYCERIN FINTOP SIBET NITAZET-O ONABET ESOZ - D COLY-MONAS PALNOX AIRTEC-FB BORTRAC GEFTIB TAZRET EVERMIL GLUCAR ZINOX TACROZ FORTE FLEXILOR MIGNAR ASCORIL PLUS TACROZ

 Group Companies

Ratios

Sales Growth

1 Year12.74%

3 Year5.7%

5 Year4.36%

Profit Growth

1 Year21.77%

3 Year17.59%

5 Year2.13%

ROE%

1 Year11.78%

3 Year12.36%

5 Year14.56%

ROCE %

1 Year12.54%

3 Year13.19%

5 Year15.43%

Interest Cover Ratio

6.98558446117243

CFO/PAT (5 Yr. Avg.)

0.843617981476078

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2021 46.63 0
Mar 2021 46.63 0
Dec 2020 46.63 0
Sep 2020 46.63 0
Jun 2020 46.62 0

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Net Sales 1682.92 2062.17 1972.48 1850.37 2142.12
Total Expenditure 1174.18 1566.81 1442.24 1494.36 1585.47
Operating Profit 508.74 495.36 530.24 356.01 556.65
Other Income 134.85 63.4 81.13 116.86 138.21
Interest 59.94 60.41 83.04 62.51 59.02
Depreciation 35.81 36.79 41.21 37 37.44
Exceptional Items 27.99 0 45.9 0 0
Profit Before Tax 575.84 461.55 533.01 373.36 598.4
Tax 113.36 58.68 90.69 31.59 108.98
Profit After Tax 462.48 402.88 442.33 341.78 489.42
Adjusted EPS (Rs) 16.39 14.28 15.68 12.11 17.34

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 7989.23 6408.54 7009.17 6712.63 7567.93
Total Expenditure 5090.59 5082.89 5478.85 5408.4 5677.59
Operating Profit 2898.64 1325.66 1530.31 1304.23 1890.34
Other Income 148.24 179.99 475.61 606.79 396.24
Interest 152.6 190.9 223.81 256.39 265.9
Depreciation 104.93 95.93 106.28 138.54 150.82
Exceptional Items -236.45 0 345.19 18.55 73.89
Profit Before Tax 2552.9 1218.83 2021.02 1534.64 1943.76
Tax 412.29 204.48 398.91 180.1 294.31
Net Profit 2140.61 1014.35 1622.11 1354.55 1649.45
Adjusted EPS (Rs.) 75.86 35.95 57.49 48 58.46

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 28.22 28.22 28.22 28.22 28.22
Total Reserves 9408.4 10363.22 11913.87 13198.05 14781.29
Borrowings 2589.35 2686.03 2831.45 3131.17 3112.58
Other N/C liabilities 399.73 -658.02 -623.63 389.35 1150.51
Current liabilities 2898.67 2184.8 2280.65 2991.54 3934.34
Total Liabilities 15324.37 14604.26 16430.56 19738.33 23006.93
Assets
Net Block 1596.37 1699.12 1413.48 1611.95 1722.49
Capital WIP 235.14 354.04 209.18 152.5 93.31
Intangible WIP 35.52 65.63 77.02 47.52 38.09
Investments 1866.7 3212.68 3268.75 4713.93 6989.95
Loans & Advances 4713.19 3388.72 6306.95 8182.74 7818.27
Other N/C Assets 0.13 8.8 14.04 2.78 4.72
Current Assets 6877.32 5875.25 5141.15 5026.92 6340.11
Total Assets 15324.37 14604.26 16430.56 19738.33 23006.93

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 2552.9 1218.83 2021.02 1534.64 1943.76
Adjustment 507.42 133.67 -354.75 -107.18 235.11
Changes in Assets & Liabilities -1536.09 63.29 1221.78 491.01 -599.61
Tax Paid -646.51 -292.07 -398.47 -339.35 -335.84
Operating Cash Flow 877.72 1123.72 2489.58 1579.12 1243.42
Investing Cash Flow -2580.46 -1136.98 -2255.53 -1607.41 -1235.19
Financing Cash Flow 1879.38 -61.58 -155.11 -139.42 -80.79
Net Cash Flow 176.64 -74.83 78.95 -167.71 -72.57

Corporate Actions

Super Investors

Investors Details

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Public 24.44 23.13 17.46 18.38 16.82
iepf 0.07 0.08 0.08 0.08 0.08
bajaj allianz life insura... 1.28 1.42 0 0 0
qualified institutional b... 0 0 0 0 0
ashish dhawan 1.24 1.24 1.24 1.51 1.81
hdfc life insurance compa... 1.28 1.28 0 0 0
life insurance corporatio... 0 1.81 0 0 0
qualified institutional b... 0 5.02 0 0 0
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
FII/DII 28.93 30.25 35.91 35 36.55
franklin templeton invest... 0 0 0 0 0
hsbc pooled investment fu... 2.34 2.79 3.13 3.45 3.25
lic of india child fortun... 0 0 0 0 0
hdfc trustee company ltd.... 0 0 0 0 0
hdfc trustee company ltd.... 0 2.25 0 2.15 2.26
hsbc global investment fu... 0 1.16 1.44 1.78 1.32
ntasian emerging leaders ... 0 0 0 0 0
hdfc trustee company ltd ... 2.33 0 2.13 0 0
life insurance corporatio... 1.75 0 1.81 0 1.76
ntasain discovery master ... 0 1.15 1.59 1.88 2.05
bajaj allianz life insura... 0 0 1.61 1.39 1.13
hdfc life insurance compa... 0 0 1.28 1.24 0
qualified institutional b... 0 0 5.26 5.29 4.74
ellipsis partners llc 0 0 0 1.08 1.29
life insurance corporatio... 0 0 0 1.76 0
government pension fund g... 0 0 0 0 1.52

Glenmark Pharma Stock Price Analysis and Quick Research Report. Is Glenmark Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Glenmark Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 1579.118 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Glenmark Pharma has a Debt to Equity ratio of 0.2705 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Glenmark Pharma , the EPS growth was -16.4946857550403 % which is bad for the company.
     
  • Operating profit margin: It determines a companys potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Glenmark Pharma has OPM of 19.4294904635753 % which is a good sign for profitability.
     
  • ROE: Glenmark Pharma have a average ROE of 10.7743071827084 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholders fund is used for generating profits.
Brief about Glenmark Pharma

Write us

Find us at the office

Blotner- Kwas street no. 55, 39246 Canberra, Australia

Give us a ring

Dymon Rothfuss
+78 715 483 676
Mon - Fri, 10:00-22:00

Write us